Market Closed -
Nasdaq
01:30:00 29/06/2024 am IST
|
5-day change
|
1st Jan Change
|
1.82
USD
|
-2.67%
|
|
+2.25%
|
+3.41%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
160
|
99.9
|
112.2
|
39.57
|
86.31
|
113.8
|
-
|
-
|
Enterprise Value (EV)
1 |
160
|
99.9
|
112.2
|
39.57
|
86.31
|
113.8
|
113.8
|
113.8
|
P/E ratio
|
-3.42
x
|
-17.8
x
|
-2.34
x
|
-0.96
x
|
-3.14
x
|
-3.79
x
|
-3.34
x
|
-2.84
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
16.9
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
16.9
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.37
x
|
-
|
-3.06
x
|
-1.45
x
|
-
|
-4.95
x
|
-3.79
x
|
-2.42
x
|
FCF Yield
|
-22.9%
|
-
|
-32.7%
|
-69%
|
-
|
-20.2%
|
-26.4%
|
-41.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
29,405
|
28,062
|
46,548
|
46,554
|
49,039
|
62,551
|
-
|
-
|
Reference price
2 |
5.440
|
3.560
|
2.410
|
0.8500
|
1.760
|
1.820
|
1.820
|
1.820
|
Announcement Date
|
05/03/20
|
25/03/21
|
10/03/22
|
28/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
6.718
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.85
|
-43.76
|
-38.63
|
-32.56
|
-23.41
|
-32.16
|
-46.17
|
-56.37
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-839.16%
|
Earnings before Tax (EBT)
1 |
-46.67
|
-5.995
|
-43.24
|
-41.31
|
-27.03
|
-28.91
|
-44.32
|
-56.54
|
Net income
1 |
-46.67
|
-5.995
|
-43.24
|
-41.31
|
-27.03
|
-30.32
|
-45.74
|
-55.65
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-828.45%
|
EPS
2 |
-1.590
|
-0.2000
|
-1.030
|
-0.8900
|
-0.5600
|
-0.4800
|
-0.5450
|
-0.6400
|
Free Cash Flow
1 |
-36.58
|
-
|
-36.72
|
-27.29
|
-
|
-23
|
-30
|
-47
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-699.67%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/03/20
|
25/03/21
|
10/03/22
|
28/03/23
|
19/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.81
|
-7.413
|
-7.013
|
-12.47
|
-5.666
|
-6.574
|
-5.622
|
-5.56
|
-5.651
|
-6.253
|
-7.502
|
-8.718
|
-9.697
|
-10.7
|
-11.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.236
|
-8.297
|
-8.363
|
-14.83
|
-9.816
|
-7.873
|
-6.503
|
-6
|
-6.653
|
-5.701
|
-6.968
|
-7.495
|
-8.569
|
-10.3
|
-10
|
Net income
1 |
-9.236
|
-8.297
|
-8.363
|
-14.83
|
-9.816
|
-7.873
|
-6.503
|
-6
|
-6.653
|
-5.701
|
-7.263
|
-8.121
|
-9.177
|
-10.3
|
-9.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.2000
|
-0.1800
|
-0.1800
|
-0.3200
|
-0.2100
|
-0.1700
|
-0.1400
|
-0.1200
|
-0.1400
|
-0.1200
|
-0.1150
|
-0.1225
|
-0.1300
|
-0.1500
|
-0.1500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/22
|
05/05/22
|
08/08/22
|
03/11/22
|
28/03/23
|
08/05/23
|
08/08/23
|
07/11/23
|
19/03/24
|
06/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-36.6
|
-
|
-36.7
|
-27.3
|
-
|
-23
|
-30
|
-47
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.03
|
-
|
0.01
|
0.27
|
-
|
-
|
1
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
14.89%
|
Announcement Date
|
05/03/20
|
25/03/21
|
10/03/22
|
28/03/23
|
19/03/24
|
-
|
-
|
-
|
Last Close Price
1.82
USD Average target price
7.833
USD Spread / Average Target +330.40% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.41% | 11Cr | | +19.41% | 4.55TCr | | -8.62% | 3.85TCr | | +38.37% | 3.81TCr | | +26.95% | 3.07TCr | | -13.50% | 2.6TCr | | +10.74% | 2.59TCr | | +44.87% | 1.41TCr | | +34.36% | 1.27TCr | | -7.14% | 1.13TCr |
Other Biotechnology & Medical Research
|